Evotec takes charge for end of diabetes drug development

BERLIN, Sept 8 (Reuters) - German biotechnology company Evotec said on Monday it would take an impairment charge of 8.7 million euros ($11.3 million) after one of its advanced projects, diabetes drug Diapep277, was terminated.